4/A: Palvella Therapeutics Officer Kathleen Goin Awarded Stock Options
SEC Form 4/A
Kathleen Goin, Chief Operating Officer of Palvella Therapeutics, received incentive and non-qualified stock options on February 5, 2025.
Summary
- Kathleen Goin, Chief Operating Officer of Palvella Therapeutics, was granted stock options on February 5, 2025.
- The grant includes incentive stock options for 5,373 shares and non-qualified stock options for 123,559 shares, both with an exercise price of $14.76.
- The options vest monthly over 48 months and expire on February 5, 2035.
- This Form 4/A is an amendment to a previous filing to reflect a name change for the reporting person.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
- The size of the grant is likely determined by factors such as the executive's role, performance, and industry benchmarks for similar positions at comparable companies such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Amgen.
Stakeholder Impact
- The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
- The grant incentivizes the COO to contribute to the company's success, which could benefit employees and other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of stock option grant |
| 02/07/2025 | Date of original filing (amended) |
| 02/10/2025 | Date of signature on the amended form |
| 02/05/2035 | Expiration date of the stock options |
Keywords
stock options, Form 4, Palvella Therapeutics, Kathleen Goin, incentive stock options, non-qualified stock options, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.